Rise and shine, another busy day is on the way. And it feels particularly busy. Between the pandemic and protests on this side of the pond, the world seems to be spinning a bit faster than usual, yes? For many, this can make it harder to go about your usual routines, but do your best. Grab a cup of stimulation and dig into a few tidbits we have assembled for you. Meanwhile, we hope today brings better things. …

One of the most widely prescribed antidepressants in the U.S. has fallen into short supply, as demand increases due to mental health strains caused by the Covid-19 pandemic, Bloomberg News notes. Late last week, the Food and Drug Administration added Zoloft, which is sold under the generic name sertraline and was first approved in the U.S. in 1991, to its list of drugs in shortage. The tablet is used to treat a range of conditions, including depression, obsessive-compulsive disorder, and post-traumatic stress disorder.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy